Lineage Cell Therapeutics, Inc.
DE ˙ DB ˙ US53566P1093
€ 1,01 ↓ -0.04 (-3.63%)
2026-06-03
PREÇO DA AÇÃO
SecurityDE:BT3 / Lineage Cell Therapeutics, Inc.
InstitutionFmr Llc
Latest Disclosed Ownership193,308 shares
Latest Disclosed Value $ 305,426
Fmr Llc reports 0.70% increase in ownership of BT3 / Lineage Cell Therapeutics, Inc.

On May 15, 2026 - Fmr Llc filed a 13F-HR form disclosing ownership of 193,308 shares of Lineage Cell Therapeutics, Inc. (DE:BT3) valued at $243,568 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 191,960 shares of Lineage Cell Therapeutics, Inc.. This represents a change in shares of 0.70% during the quarter. The current value of the position is $195,241 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 193,308 1,348 0.70 305 -4.69 0.0000
2026-02-17 2025-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 191,960 -2,068 -1.07 321 -2.14 0.0000
2025-11-13 2025-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 194,028 -862 -0.44 328 85.80 0.0000
2025-08-14 2025-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 194,890 -9,216 -4.52 177 91.30 0.0000
2025-05-12 2025-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 204,106 3,201 1.59 92 -8.00 0.0000
2025-02-13 2024-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 200,905 194,495 3,034.24 101 1,900.00 0.0000
2024-11-13 2024-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 6,410 4,537 242.23 6 400.00 0.0000
2024-08-13 2024-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,873 -228 -10.85 2 -66.67 0.0000
2024-05-13 2024-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,101 751 55.63 3 200.00 0.0000
2024-02-13 2023-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,350 -94 -6.51 1 0.00 0.0000
2023-11-13 2023-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,444 -649 -31.01 2 -50.00 0.0000
2023-08-11 2023-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,093 1,249 147.99 3 100.00 0.0000
2023-08-11 2023-03-31 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 844 62 7.93 1 0.0000
2023-05-11 2023-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 844 62 1 0.0000
2023-02-13 2022-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 782 -236 -23.18 1 -100.00 0.0000
2022-11-10 2022-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,018 -4,408 -81.24 1 -88.89 0.0000
2022-08-12 2022-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 5,426 3,744 222.59 9 350.00 0.0000
2022-05-13 2022-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,682 1,680 84,000.00 2 0.0000
2022-02-14 2021-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2 0 0.00 0 0.0000
2022-02-14 2021-09-30 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 2 -3 -60.00 0 0.0000
2021-11-15 2021-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2 -3 0 0.0000
2021-08-13 2021-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 5 5 0 0.0000
2020-05-14 2020-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 0 -500 -100.00 0 0.0000
2020-02-07 2019-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 500 500 0 0.0000
2019-11-13 2019-09-30 13F BIOTIME COM 09066L105 0 -493 -100.00 0 -100.00
2019-08-13 2019-06-30 13F BIOTIME COM 09066L105 493 473 2,365.00 1 0.0000
2019-05-13 2019-03-31 13F BIOTIME COM 09066L105 20 -613,328 -100.00 0 -100.00
2014-02-13 2013-12-31 13F BIOTIME COM 09066L105 613,348 -838,152 -57.74 2,208 -59.97 0.0003
2013-11-14 2013-09-30 13F BIOTIME COM 09066L105 1,451,500 -66,400 -4.37 5,516 -8.23 0.0008
2013-09-24 2013-06-30 13F/A-1 BIOTIME COM 09066L105 1,517,900 1,517,900 6,011 0.0010
2013-08-14 2013-06-30 13F BIOTIME COM 09066L105 1,517,900 6,011 0.0010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.